[go: up one dir, main page]

GB202105186D0 - Pyrrolobenzodiazepine conjugates - Google Patents

Pyrrolobenzodiazepine conjugates

Info

Publication number
GB202105186D0
GB202105186D0 GBGB2105186.7A GB202105186A GB202105186D0 GB 202105186 D0 GB202105186 D0 GB 202105186D0 GB 202105186 A GB202105186 A GB 202105186A GB 202105186 D0 GB202105186 D0 GB 202105186D0
Authority
GB
United Kingdom
Prior art keywords
pyrrolobenzodiazepine conjugates
pyrrolobenzodiazepine
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2105186.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Priority to GBGB2105186.7A priority Critical patent/GB202105186D0/en
Publication of GB202105186D0 publication Critical patent/GB202105186D0/en
Priority to PCT/EP2022/059733 priority patent/WO2022218973A2/en
Priority to TW111113931A priority patent/TW202308697A/en
Priority to ARP220100927A priority patent/AR125338A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB2105186.7A 2021-04-12 2021-04-12 Pyrrolobenzodiazepine conjugates Ceased GB202105186D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB2105186.7A GB202105186D0 (en) 2021-04-12 2021-04-12 Pyrrolobenzodiazepine conjugates
PCT/EP2022/059733 WO2022218973A2 (en) 2021-04-12 2022-04-12 Pyrrolobenzodiazepine conjugates
TW111113931A TW202308697A (en) 2021-04-12 2022-04-12 Pyrrolobenzodiazepine conjugates
ARP220100927A AR125338A1 (en) 2021-04-12 2022-04-12 PYRROLOBENZODIAZEPINE CONJUGATES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2105186.7A GB202105186D0 (en) 2021-04-12 2021-04-12 Pyrrolobenzodiazepine conjugates

Publications (1)

Publication Number Publication Date
GB202105186D0 true GB202105186D0 (en) 2021-05-26

Family

ID=75949544

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2105186.7A Ceased GB202105186D0 (en) 2021-04-12 2021-04-12 Pyrrolobenzodiazepine conjugates

Country Status (4)

Country Link
AR (1) AR125338A1 (en)
GB (1) GB202105186D0 (en)
TW (1) TW202308697A (en)
WO (1) WO2022218973A2 (en)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180487A (en) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd Antibiotic dc-81 and its preparation
EP1720881B9 (en) 2004-03-01 2013-04-17 Spirogen Sàrl 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins
EP1879901B1 (en) 2005-04-21 2009-12-23 Spirogen Limited Pyrrolobenzodiazepines
EP1813614B1 (en) 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
PT2099823E (en) 2006-12-01 2014-12-22 Seattle Genetics Inc Variant target binding agents and uses thereof
MA34277B1 (en) 2010-04-15 2013-06-01 Spirogen Developments Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
JP6014596B2 (en) 2010-11-09 2016-10-25 メディミューン,エルエルシー Antibody scaffold for homogeneous conjugation
KR101412875B1 (en) 2012-10-04 2014-07-02 삼성전기주식회사 Gate driving circuit and inverter having the same
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドMedImmune Limited Pyrrolobenzodiazepines and their complexes
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
ES2719584T3 (en) 2014-04-11 2019-07-11 Medimmune Llc Conjugated compounds comprising genetically engineered antibodies modified with cysteine
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) * 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20190083654A (en) 2016-11-10 2019-07-12 메디뮨 엘엘씨 Binding molecules specific for ASCT2 and uses thereof
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3801630A1 (en) 2018-05-25 2021-04-14 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2018430758B2 (en) * 2018-07-05 2022-01-27 Hangzhou Dac Biotech Co., Ltd Cross-linked pyrrolobenzodiazepine dimer (PBD) derivative and its conjugates
AU2018445278B2 (en) * 2018-10-12 2022-07-28 Hangzhou Dac Biotech Co., Ltd Conjugation linkers containing 2,3-diaminosuccinyl group
GB2581394A (en) * 2019-02-18 2020-08-19 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date
WO2022218973A3 (en) 2022-12-22
WO2022218973A2 (en) 2022-10-20
AR125338A1 (en) 2023-07-05
TW202308697A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
IL315508A (en) Camptothecin conjugates
IL287391A (en) Amatoxin antibody-drug conjugates and uses thereof
IL272625B1 (en) Pyrrolobenzodiazepine conjugates
IL269945B (en) Pyrrolobenzodiazepine conjugates
IL299362A (en) Antibody-drug conjugates comprising anti-b7-h3 antibodies
IL308811A (en) Neodegrader conjugates
IL291312A (en) Anti-ptcra antibody-drug conjugates and uses thereof
IL318188A (en) Antibody-drug conjugates
GB2594753B (en) Antibody-drug conjugates
GB201820864D0 (en) Antibody-drug conjugates
GB201902182D0 (en) Pyrrolobenzodiazepines and conjugates thereof
GB202105187D0 (en) Pyrrolobenzodiazepine conjugates
GB202105186D0 (en) Pyrrolobenzodiazepine conjugates
IL288681A (en) Pyrrolobenzodiazepine-antibody conjugates
GB201908126D0 (en) Pyrrolobenzodiazepine conjugates
GB201905117D0 (en) Pyrrolobenzodiazepine conjugates
GB201906997D0 (en) Conjugates
IL319822A (en) Neodegrader conjugates
GB202210058D0 (en) Conjugates
GB202000121D0 (en) Compounds and conjugates
GB201817088D0 (en) Pyrrolobenzodiazepine conjugates
GB201817110D0 (en) Pyrrolobenzodiazepine conjugates
IL314507A (en) Theragnostic folate conjugates
IL324828A (en) Ligand-polar drug conjugates
HK40086516A (en) Antibody-drug conjugates

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)